Enrolling 100% of Total Participants for a Phase 3 Rare Cardiology Trial

Science 37 enrolled all study participants across 19 U.S. states as a single Direct-to-Patient Site, successfully managing a difficult-to-enroll population with a rare genetic disorder, limited eligible patients, broad geographic dispersion, and a complex, closely monitored, long-duration (40 months with OLE) protocol.